Mission Creek Capital Partners Inc. Has $255,000 Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Mission Creek Capital Partners Inc. lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 8.1% in the third quarter, HoldingsChannel reports. The firm owned 3,045 shares of the biopharmaceutical company’s stock after selling 267 shares during the period. Mission Creek Capital Partners Inc.’s holdings in Gilead Sciences were worth $255,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in GILD. Motley Fool Asset Management LLC increased its position in Gilead Sciences by 6.1% in the 3rd quarter. Motley Fool Asset Management LLC now owns 58,425 shares of the biopharmaceutical company’s stock valued at $4,904,000 after acquiring an additional 3,348 shares in the last quarter. IHT Wealth Management LLC increased its position in Gilead Sciences by 2.5% in the 3rd quarter. IHT Wealth Management LLC now owns 13,146 shares of the biopharmaceutical company’s stock valued at $1,102,000 after acquiring an additional 319 shares in the last quarter. Investment Management Corp of Ontario increased its position in Gilead Sciences by 43.1% in the 3rd quarter. Investment Management Corp of Ontario now owns 144,048 shares of the biopharmaceutical company’s stock valued at $12,077,000 after acquiring an additional 43,369 shares in the last quarter. Janus Henderson Group PLC increased its position in Gilead Sciences by 5.9% in the 3rd quarter. Janus Henderson Group PLC now owns 1,761,561 shares of the biopharmaceutical company’s stock valued at $147,688,000 after acquiring an additional 98,067 shares in the last quarter. Finally, Harmony Asset Management LLC increased its position in Gilead Sciences by 16.6% in the 3rd quarter. Harmony Asset Management LLC now owns 4,458 shares of the biopharmaceutical company’s stock valued at $374,000 after acquiring an additional 634 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the subject of several research reports. Barclays raised their price objective on shares of Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a research report on Thursday, November 7th. Royal Bank of Canada lifted their price target on shares of Gilead Sciences from $81.00 to $84.00 and gave the stock a “sector perform” rating in a research report on Monday, November 18th. Oppenheimer lifted their price target on shares of Gilead Sciences from $95.00 to $105.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Wells Fargo & Company lifted their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Finally, Leerink Partnrs upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. Twelve equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $95.41.

Insider Transactions at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 248,645 shares of the business’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the sale, the chief financial officer now owns 138,919 shares of the company’s stock, valued at $12,886,126.44. The trade was a 64.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the transaction, the insider now owns 100,189 shares in the company, valued at approximately $8,398,843.87. The trade was a 1.96 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 476,591 shares of company stock valued at $43,747,615 over the last 90 days. 0.16% of the stock is owned by corporate insiders.

Gilead Sciences Stock Performance

Shares of GILD opened at $91.59 on Thursday. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.10 and a current ratio of 1.26. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90. The firm’s 50 day moving average price is $88.82 and its two-hundred day moving average price is $78.29. The firm has a market cap of $114.15 billion, a P/E ratio of 1,017.67, a PEG ratio of 2.92 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business’s revenue was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.29 earnings per share. On average, analysts forecast that Gilead Sciences, Inc. will post 4.37 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be given a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.36%. The ex-dividend date of this dividend is Friday, December 13th. Gilead Sciences’s dividend payout ratio is presently 3,422.22%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.